6,000, 7,000, 10,000? Why Counting Rare Diseases Is So Difficult
Executive Summary
FDA, NIH, sponsors and others use different figures, but some want everyone will settle on 10,000 for policy discussions, advocacy and research.
You may also be interested in...
India Exempts Rare Disease Drugs, Keytruda From Customs Duty - Is It Enough?
India has exempted imports of top-selling oncology drug Merck’s Keytruda from customs duty as also rare disease drugs listed in the National Policy For Rare Diseases. However, patient advocacy groups feel more fiscal measures and manufacturing incentives are needed to improve access
Ultra-Rare Orphan Drugs: Advocates Begin Laying Groundwork For New Incentive, Special Pathway
Rare disease advocates push for National Academies of Sciences, Engineering and Medicine study on how or whether ultra-rare should be defined, which could create legislative pressure. In an interview, Ultragenyx CEO Emil Kakkis suggests patient thresholds, accelerated approval triggers.
Does The Orphan Drug Act Need A Tune-Up?
A better description of the US FDA’s regulatory flexibility may be necessary, but tinkering with the foundational law for rare disease drug development could open the door for more substantial and unwanted changes.